AstraZeneca Cultivates Oncology Pipeline With Pinetree Pact

Deal Snapshot: Degrading rather than inhibiting a target protein has emerged as one of the most promising approaches in drug discovery and AstraZeneca is paying handsomely to advance its presence in the space.